Janus Henderson Group PLC Increases Stock Position in Enanta Pharmaceuticals, Inc. $ENTA

Janus Henderson Group PLC boosted its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 1.5% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,784,055 shares of the biotechnology company’s stock after buying an additional 54,396 shares during the quarter. Janus Henderson Group PLC owned approximately 0.13% of Enanta Pharmaceuticals worth $47,717,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its stake in shares of Enanta Pharmaceuticals by 674.7% during the 1st quarter. AQR Capital Management LLC now owns 357,109 shares of the biotechnology company’s stock worth $1,971,000 after acquiring an additional 311,010 shares in the last quarter. Millennium Management LLC increased its stake in shares of Enanta Pharmaceuticals by 50.2% in the 1st quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock valued at $7,435,000 after purchasing an additional 449,945 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Enanta Pharmaceuticals by 5.3% in the 1st quarter. Goldman Sachs Group Inc. now owns 130,410 shares of the biotechnology company’s stock valued at $720,000 after purchasing an additional 6,549 shares in the last quarter. Invesco Ltd. raised its holdings in Enanta Pharmaceuticals by 4.3% in the 2nd quarter. Invesco Ltd. now owns 62,884 shares of the biotechnology company’s stock worth $475,000 after purchasing an additional 2,607 shares during the period. Finally, Marshall Wace LLP raised its holdings in Enanta Pharmaceuticals by 0.8% in the 2nd quarter. Marshall Wace LLP now owns 857,412 shares of the biotechnology company’s stock worth $6,482,000 after purchasing an additional 6,522 shares during the period. Hedge funds and other institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Stock Down 3.1%

ENTA opened at $12.60 on Friday. The company has a market cap of $366.41 million, a PE ratio of -4.86 and a beta of 0.96. Enanta Pharmaceuticals, Inc. has a twelve month low of $6.45 and a twelve month high of $17.15. The company has a 50-day moving average price of $13.09 and a 200 day moving average price of $13.41.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.01. Enanta Pharmaceuticals had a negative return on equity of 64.04% and a negative net margin of 89.56%.The company had revenue of $17.16 million for the quarter, compared to analysts’ expectations of $17.03 million. As a group, sell-side analysts expect that Enanta Pharmaceuticals, Inc. will post -1.79 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on ENTA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, June 23rd. Finally, Wall Street Zen cut shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Enanta Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $20.29.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct?acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.